BioXion Platform Showcase

Overview

Program Intelligence — real-time readiness at a glance

The central command hub of BioXion aggregates live data across all modules into a single program readiness score. Critical risks are flagged with severity weighting, active milestones tracked with days-to-deadline counters, and cross-module dependencies surfaced automatically. CMC Directors and program leads get a complete picture of program health — without opening a single spreadsheet or status report.

✦ AI continuously evaluates over 100 CMC-specific rule conditions, calculates readiness impact weights per risk item, and generates prioritized action recommendations — each referencing the exact ICH, FDA, or EMA guideline that applies.

CMC Development

AI-generated CMC roadmap across all development phases

BioXion generates a complete, phase-appropriate CMC development roadmap from Preclinical through IND-enabling, Phase I, Phase II, Phase III, and all the way to Commercial. A dedicated Gene Therapy module addresses the unique CMC complexity of viral vectors — including vector genome characterization, adventitious agent testing, and GMP requirements that differ fundamentally from classical biologics.

✦ Roadmaps are dynamically generated — not templated PDFs. The AI engine constructs each plan based on current regulatory expectations, your modality, and development stage. Every step links to the applicable ICH, FDA, or EMA guideline and updates automatically as guidance evolves.

CMC Development

Live phase-by-phase CMC step tracking

Once generated, the CMC roadmap becomes a fully live tracker. Steps are organized by development phase and broken down by functional area — Drug Substance, Drug Product, Analytical. The platform supports the full arc from first cell line development in Preclinical to process validation and commercial manufacturing readiness, with full traceability across every step.

✦ The AI navigator monitors completion velocity against submission timelines. When a step risks delaying an IND or BLA milestone, BioXion generates a targeted alert with specific corrective actions — giving teams weeks of lead time rather than days.

CDMO Management

Full CDMO partner oversight with AI reliability scoring

BioXion centralizes the management of all contract manufacturing relationships — tracking activity type, manufacturing site, program, development phase, status, risk level, and next milestone per partner. Tech transfer milestones, GMP batch deliverables, and audit findings are monitored continuously across all CDMOs simultaneously.

✦ The AI Partner Reliability Index scores each CDMO based on milestone adherence, audit findings, deviation history, and tech transfer performance — replacing subjective relationship management with quantified risk intelligence.

Quality Systems

Deviations, CAPAs, change control and audit readiness

BioXion Quality Systems provides a unified view of all quality events across the program — deviations, CAPAs, change controls, and upcoming audits. Every quality event is linked directly to the relevant manufacturing step, analytical method, or CDMO activity, connecting quality data to full CMC program context.

✦ AI correlates quality event patterns with upstream CMC activity data to distinguish isolated incidents from systemic process signals — providing early warning intelligence that traditional standalone QMS systems are not designed to deliver.

Analytical Development

Method lifecycle intelligence from development to transfer

BioXion Analytical Intelligence covers the full analytical method lifecycle — development, qualification, validation, tech transfer, and stability. All method types are tracked (HPLC, LC-MS, Bioassay, qPCR), with complete performance audit trail linked to the CMC program timeline and active stability studies monitored in real time.

✦ AI monitors method performance metrics and triggers alerts when parameters approach ICH Q2(R2) acceptance thresholds — before the data enters a formal review cycle. Method transfer readiness is assessed automatically against destination site capabilities.

Supply Chain

Inventory, logistics and cold chain intelligence

BioXion Supply Chain Intelligence provides real-time visibility into material availability, shipment status, and cold chain integrity across all CDMO sites. Drug substance, drug product, and excipient inventory is tracked with reorder triggers, expiry management, and location-level granularity across distribution, demand planning, and supplier sub-modules.

✦ AI Supply Chain Insights ranks risks by clinical program impact. A cold chain temperature excursion at a CDMO site triggers an immediate cross-module alert linked to the affected batch and the next scheduled manufacturing milestone.

Regulatory Intelligence

Global submissions, compliance and AI readiness scoring

BioXion Regulatory Intelligence manages the full submission portfolio — IND, BLA, CTA, MAA, and CMC variations — across FDA, EMA, and Swissmedic. Each submission carries an AI Readiness Score quantifying how complete the CMC data package is. Regulatory timelines, market requirements, post-approval commitments, and new guidance updates are tracked end-to-end.

✦ AI monitors new guidance publications from FDA, EMA, ICH, and Swissmedic in real time — automatically flagging where updated guidance creates a gap in your current CMC data package or submission strategy before it becomes a deficiency.